13F Holdings
中文EN

EOLS Evolus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—

Margins

Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%

Returns

ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$297.18M$266.27M$202.09M$148.62M$99.67M
Cost of revenue$100.07M$83.97M$64.51M$58.84M$43.53M
Gross profit$197.11M$182.30M$137.57M$89.77M$56.14M
R&D expense$9.58M$9.17M$6.56M$4.74M$2.06M
SG&A expense$220.79M$198.03M$164.94M$141.84M$112.07M
Operating income-$32.66M-$34.41M-$49.23M-$65.33M-$44.41M
Interest expense$19.69M$18.73M$13.83M$9.10M$1.40M
Pretax income-$50.96M-$49.76M-$61.51M-$74.32M-$46.77M
Income tax$677,000$664,000$176,000$95,000$42,000
Net income-$51.64M-$50.42M-$61.69M-$74.41M-$46.81M
EBITDA-$25.16M-$29.11M-$44.10M-$61.61M-$38.78M
EPS (basic)-0.80-0.81-1.08-1.33-0.94
EPS (diluted)-0.80-0.81-1.08-1.33-0.94
Weighted avg. shares (diluted)64.47M62.02M56.92M56.07M49.77M
Balance sheet
Cash & equivalents$53.83M$86.95M$62.84M$53.92M$146.26M
Short-term investments————$0
Receivables$54.70M$47.68M$30.53M$22.45M$14.66M
Inventory$26.96M$12.16M$11.00M$18.85M$1.76M
Current assets$142.92M$151.34M$112.42M$100.80M$178.80M
PP&E, net$5.37M$3.22M$2.09M$2.62M$1.37M
Goodwill$21.21M$21.21M$21.21M$21.21M$21.21M
Intangibles$48.04M$48.75M$47.11M$48.60M$50.62M
Total assets$225.87M$232.57M$189.00M$177.98M$257.48M
Current liabilities$75.31M$62.96M$48.29M$46.51M$57.66M
Long-term debt$146.10M$121.51M$120.36M$71.88M$71.22M
Total debt$146.10M$121.51M$120.36M$71.88M$71.22M
Total liabilities$248.97M$227.05M$209.69M$159.48M$175.61M
Shareholders' equity-$23.11M$5.52M-$20.69M$18.50M$81.88M
Net debt$92.27M$34.55M$57.52M$17.96M-$75.03M
Shares outstanding65.01M63.50M57.82M56.26M55.58M
Cash flow statement
Operating cash flow-$42.27M-$18.00M-$34.01M-$84.91M-$33.39M
Capital expenditure$3.44M$1.47M$473,000$1.62M$393,000
Free cash flow-$45.71M-$19.47M-$34.48M-$86.53M-$33.78M
Investing cash flow-$8.45M-$4.82M-$1.63M-$2.94M$4.03M
Financing cash flow$17.34M$47.41M$44.64M-$4.15M$73.05M
Depreciation & amortization$7.51M$5.30M$5.13M$3.72M$5.62M
Stock-based compensation$20.70M$22.25M$16.46M$10.83M$9.58M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.